Cost-Minimization Analysis of Delafloxacin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Jordan

OBJECTIVES: Skin and skin structure infections are among the most widespread infectious diseases. Over the past two decades, methicillin-resistant Staphylococcus aureus has become a common cause of purulent skin and soft tissue infections. Previous studies demonstrated the non-inferiority of delafloxacin compared to "Piperacillin/Tazobactam + Vancomycin" or "Meropenem + Vancomycin" for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The aim of this study was to determine the relative cost difference between delafloxacin and standard of care for the treatment of ABSSI using a cost-minimization analysis in Jordan.

METHODS: We conducted a cost minimization analysis to compare the costs of treating ABSSI with delafloxacin, option A (Piperacillin/Tazobactam + Vancomycin), and option B (Meropenem + Vancomycin). The cost of medications, the cost of medication administration, and hospitalization costs were calculated as direct costs associated with ABSSSI management. The Jordanian Food and Drug Administration was consulted for information on medication prices. The cost of hospitalization was estimated from four main private hospitals in Jordan.

RESULTS: The total cost of the delafloxacin treatment option was 1,631.8 Jordanian Dinar (JOD) (one JOD equals 1.41 USD), compared with 3,675.4 JOD and 3,703.6 JOD for treatment options A and B, respectively. The main cost driver that contributed to the most significant difference in treatment cost among different treatment options was the infusion administration cost related to longer length of hospital stay associated with other treatment options (Piperacillin/Tazobactam + Vancomycin or Meropenem + Vancomycin). The overall cost savings associated with the use of delafloxacin are estimated to be around 2,043.7 JOD and 2,071.8 JOD for options A and B, respectively.

CONCLUSIONS: Delafloxacin is a cost-saving treatment option for patients with ABSSSI in Jordan. Our study findings can help clinicians and decision makers in the healthcare sector prescribe medications for patients with ABSSSI at lower costs while maintaining the efficacy.